B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6
B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.
Read original at benzingaStocks · News reference
Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 9:04 PM
- Checked
- Aug 10, 2026, 9:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Sana Biotechnology, Inc. (SANA)
Filed: 2026-08-10 AccNo: 0001193125-26-342371 Size: 541 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarSana Biotechnolog Publishes Peer-Reviewed Letter To Editor In New England Journal Of Medicine
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025Seminal Study Successfully Achieved Primary and Secondary Endpoints,
Read original at benzinga